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Aims International guidelines are frequently not implemented in the elderly population with heart failure (HF). This study
determined the management of octogenarians with HF enrolled in Euro Heart Failure Survey II (EHFS II) (2004–05).
Methods
and results
We compared the clinical profile, 12 month outcomes, and management modalities between 741 octogenarians
(median age 83.7 years) and 2836 younger patients (median age 68.4 years) hospitalized for acute/decompensated
HF. Management modalities were also compared with those observed in EHFS I (2000–01). Female gender, new
onset HF (de novo), hypertension, atrial fibrillation, co-morbidities, disabilities, and low quality of life were more
common in the elderly (all P, 0.001). Mortality rates during hospital stay and during 12 months after discharge
were increased in octogenarians (10.7 vs. 5.6% and 28.4 vs. 18.5%, P, 0.001). Underuse and underdosage of medi-
cations recommended for HF were observed in the elderly. However, a significant improvement was observed when
compared with EHFS I both in the overall HF octogenarian population and in the subgroup with ejection fraction
45% for prescription rates of ACE-I/ARBs, beta-blockers, and aldosterone antagonists at discharge (82 vs. 71%;
56 vs. 29%; 54 vs. 18.5%, respectively, all P, 0.01), as well as for recommended combinations and dosage. Prescrip-
tion rates remained stable for 12 months after discharge in survivors.
Conclusion Our study confirms that the contemporary management of very elderly patients with HF remains suboptimal but that
the situation is improving.
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Introduction
Heart failure (HF) is associated with high mortality and prolonged
and frequent hospitalizations and is responsible for a tremendous
burden on health care systems.1 The prevalence of this condition
increases markedly with age.2 Several surveys, including Euro
Heart Failure Survey I (EHFS I),3 suggest that outcome is particu-
larly poor in elderly patients4 and that treatment is often
complicated by the presence of multiple co-morbid factors.4 –7
Moreover, evidence-based therapies are less frequently used and
underdosage of recommended medications is constantly observed
in the elderly.8– 11 However, EHFS I12 was performed in 2000–01
at a time when perception of guidelines for the management of HF
was less developed than it is nowadays and this survey had a
limited follow-up (FU) period of 12 weeks. The purpose of the
current study was therefore to (i) analyse the clinical profile and
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the outcome of octogenarians enrolled in the Euro Heart Failure
Survey II (EHFS II) over a 12 month period, and to (ii) see
whether management of HF improved in this more contemporary
context when compared with EHFS I.
Methods
EHFS II was conducted by the European Society of Cardiology (ESC)
between October 2004 and August 2005 and included 3580 patients
admitted to 133 participating hospitals including cardiac care units,
intensive care units, as well as on ward facilities (internal medicine
and cardiology) in 30 ESC countries.
Methodology and primary results of the survey have been detailed
elsewhere.13 In brief, EHFS II recruited patients admitted with dys-
pnoea, and verification of HF based on the presence of symptoms
and signs of HF and lung congestion on chest X-ray. Patients were
classified by the investigator according to the guidelines on acute HF
published by the ESC14 as follows:
Decompensated HF, acute pulmonary oedema, cardiogenic shock,
HF and hypertension, right HF. Clinical history, symptoms, signs,
co-morbidities, standard biology, most recent echocardiographic
data, and medications at admission and discharge were recorded (for
details, see reference 13).
For the conversion of haemoglobin (Hb) and creatinine measure-
ments from SI units, the factors given by Kratz and Lewandrowski15
were used. Anaemia was defined by the criteria of the World
Health Organization16 (Hb , 13 g/dL in men and ,12 g/dL in
women, severe anaemia by Hb, 11.5 g/dL in men and ,10.5 g/dL
in women). The glomerular filtration rate (GFR) was calculated
according to the abbreviated MDRD formula.17 Hypertension on
admission was defined as systolic blood pressure .140 mmHg or dias-
tolic blood pressure .90 mmHg. An assessment of preserved left ven-
tricular systolic function was given by echocardiographic left
ventricular ejection fraction (EF) .45%.
This analysis included 3577 patients, 741 (21%) of these patients
were 80 years and we compared their clinical profile, treatment,
and mortality with younger patients (n ¼ 2836, 79%). In three subjects
from the original EHFS II, date of birth was not available and therefore
they were not included in the present study. We also examined
the proportion of patients treated with high doses of ACE-I
(defined as in EHFS I3 by a daily dose of enalapril  20 mg, captopril 
75 mg, ramipril  5 mg, perindopril  4 mg, lisinopril  20 mg,
trandolapril  2 mg), high doses of ARB (defined by a daily dose of
candesartan  16 mg, eprosartan  600 mg, irbesartan  300 mg,
losartan  100 mg, valsartan  80 mg), and high doses of beta-
blockers (defined by a daily dose of bisoprolol  5 mg, carvedilol 
25 mg, metoprolol succinate  100 mg, atenolol  100 mg).
In the centres participating in the FU, 3178 hospital survivors were
contacted at 3 months and 12 months post-inclusion. The vital status
was ascertained for 2978 patients at median 100 days [inter-quartile
range (IQR) 92–116] post-inclusion during the 3 month FU and for
2295 patients at median 372 days (IQR 361–398) in the 1 year FU.
Adverse events [death, myocardial infarction (MI), stroke, device
implantation, rehospitalization] were recorded if they had occurred
since the last contact. For deceased patients, the date of death was col-
lected. The number of hospitalizations since the last contact, but not
their exact dates, was collected. At 3 months, 51% of the patients
were contacted by phone, 3% by written questionnaire, 27% in
person, and for 19%, a hospital record was available. Information at
1 year was obtained by phone for 49%, by written questionnaire for
6%, by patient contact for 24%, and from hospital records for 21%
of the patients. The current medication was recorded for 2464
patients within a period from 70 to 180 days post-inclusion and for
1773 patients between 300 and 540 days.
Statistical analysis
Absolute numbers and percentages are shown for categorical variables
to describe the patient population, and medians with IQR for continu-
ous variables. For descriptive purposes, binary variables were com-
pared between subgroups by Pearson’s x2 test and continuous
variables by the Mann–Whitney U test. These statistics were calcu-
lated for the available cases. Survival after discharge was estimated
by the Kaplan–Meier method and compared between age groups by
log-rank test. The cumulative incidence of the interval-censored
major adverse clinical events (MACE: death, MI, or stroke) since admis-
sion was estimated by the product-limit method for the discrete time
points discharge, 3 month FU, and 12 month FU. Rehospitalization
rates were calculated as the number of rehospitalizations divided by
person-months under observation, and rate ratios with 95% confi-
dence intervals were estimated by the Poisson regression with
additional dispersion parameter. In the octogenarians, predictors of
in-hospital mortality were analysed by multiple logistic regression
and predictors of 1 year mortality among the hospital survivors by
Cox regression. The following variables were considered as potential
predictors on the basis of clinical judgement and a P-value , 0.2 in
the univariate comparisons: age, gender, body mass index, smoking;
clinical classification; diabetes, chronic renal failure, and anaemia; pre-
cipitating conditions including acute coronary syndrome, ST-segment
elevation myocardial infarction (STEMI), arrhythmias, valvular heart
disease, and infection; on admission: somnolence or confusion, cold
peripheral temperature, systolic blood pressure, and heart rate;
serum creatinine, severe anaemia; EF and health status using the
EuroQoL-5D.18 Prescriptions of ACE-I/ARB, beta-blockers, and
statins at discharge were entered into the models of 1 year mortality.
The models were finalized regarding the results of stepwise selection
procedures using significance levels of 0.1 for entry and 0.15 for
removal. Finally, model variables without significant effect are left
only for clinical reasons. The discrimination of the logistic regression
model was assessed with the C-statistic and model calibration with
the Hosmer–Lemeshow test. For predictive purposes, the model dis-
crimination and the regression coefficients might be overestimated. In
order to assess the predictive accuracy, the models were fitted to 200
bootstrap samples and the estimated coefficients applied to the orig-
inal data set. Regression in the original sample with the resulting
linear predictor as only explanatory variable yields a slope which can
be regarded as a factor for shrinkage of the coefficients.19 The differ-
ence between the C-statistics evaluated on the bootstrap sample and
on the original sample, averaged over the 200 bootstrap replications,
is an estimate of optimism, which can be subtracted from the apparent
C-statistic in order to get a corrected value of the predictive discrimi-
nation.20 Octogenarians from EHFS II (overall population and the sub-
group with chronic HF and reduced EF) were compared with those
from EHFS I, regarding these two surveys as independent cross-
sections. The development of drug prescriptions over time was
assessed by calculating rates of continuation and discontinuation
from admission to discharge, discharge to 3 months, and 3 months
to 12 months. The development of the prescription rates was summar-
ized by multiplying the matrices of these transition probabilities in
order to avoid apparent changes in prevalence caused by mortality
or drop-out. A significance level of 0.05 was assumed for the statistical
tests. All P-values are results of two-tailed tests. The calculations were
performed using SAS& statistical software, version 9.1 (Cary,
NC, USA).
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Results
Patients and demographic characteristics
Out of 3577 patients, there were 741 octogenarians with an age of
80 years [median age 83.7 years (81.7–86.8)] and 2836 younger
patients [median age 68.4 (59.5–74.7)]. Main demographic data on
the two age groups (80 vs.,80 years) are given in Table 1.
Women represented 56% of elderly patients vs. 34% in the
younger group, P, 0.001. Octogenarians were less commonly
referred to a cardiology department than younger subjects (78
vs. 85%, P, 0.001). New onset HF (de novo) was more frequently
observed in older people. Similarly, atrial fibrillation/supraventricu-
lar tachycardia and hypertension were also more common in octo-
genarians. Co-morbidities including stroke/transient ischaemic
attack, somnolence/confusion, renal dysfunction, anaemia, and
chronic obstructive pulmonary disease (COPD) were more fre-
quent in octogenarians, whereas diabetes was less common.
Table 2 indicates lifestyle characteristics of the overall popu-
lation. Older people were less likely to live in their own home,
had more often walking disorders, self-care problems, and
needed more often help by relatives or by assistance services
than younger people.
Investigations
Renal function was significantly worse in octogenarians than in
younger patients and the prevalence of severe renal dysfunction
was increased (Table 3). Similarly, anaemia and severe anaemia
were more frequent in older people (Table 1). Echocardiography
was less often performed in octogenarians. The proportion of
patients with preserved EF (.45%) was higher in the older
group. Overall, octogenarians had a higher EF than younger sub-
jects and a smaller left ventricular end-diastolic diameter. During
hospitalization, coronary angiography was less often performed
in octogenarians.
Treatment
Comparison of heart failure therapy between
octogenarian and younger subjects
Treatment with ACE-I or ARBs, beta-blockers, and spironolactone
at the time of discharge from hospital was less commonly pre-
scribed in octogenarians than in younger patients (Figure 1). The
combination of ACE-I/ARB þ beta-blocker was less frequent in
older people (42 vs. 55%, P, 0.001), and high doses of ACE-I/
ARBs and beta-blockers were less frequently prescribed (high-
dose ACE-I/ARB 30 vs. 34.5%, P, 0.05; high-dose beta-blockers
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Table 1 Baseline clinical characteristics by age group
Age  80 years (n ¼ 741) (21%) Age, 80 years (n ¼ 2836) (79%) P-value
Age (years)a 83.7 (81.7–86.8) 68.4 (59.5–74.7) ,0.001a
Male gender 44% (327/741) 66% (1867/2836) ,0.001b
Body mass index (kg/m2)a 26.0 (23.1–28.9) 26.9 (24.4–30.4) ,0.001a
Enrolment
New onset HF (de novo) 45% (333/741) 35% (994/2836) ,0.001b
HF during past 12 months 37% (267/715) 46% (1278/2753) ,0.001b
Cardiovascular diseases
Coronary heart disease 51% (377/741) 54% (1540/2835) 0.094b
Dilated cardiomyopathy 14% (104/735) 21% (583/2823) ,0.001b
Atrial fibrillation/SVT 48% (351/738) 36% (1028/2829) ,0.001b
History of hypertension 67% (494/735) 61% (1731/2826) 0.003b
Co-morbidities
Diabetes 29% (215/739) 34% (955/2832) 0.017b
Stroke or TIA 20% (145/739) 12% (331/2829) ,0.001b
COPD 22% (164/739) 19% (526/2831) 0.027b
Anaemia (WHO definition)c 47% (345/732) 37% (1037/2786) ,0.001b
Severe anaemiad 21% (154/732) 17% (478/2786) 0.015b
Clinical examination
Systolic blood pressure (mmHg)a 140 (120–170) 130 (110–160) ,0.001a
SBP/DBP. 140/90 mmHg 50% (366/737) 41% (1153/2811) ,0.001b
Somnolence/confusion 24% (171/706) 14% (394/2754) ,0.001b
Data are presented as percentage (number/population).
HF, heart failure; SVT, supraventricular tachycardia; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic
blood pressure.
aMedian and quartiles, Mann–Whitney U test.
bPearson’s x2 test.
cHb , 13 g/dL in men, ,12 g/dL in women.
dHb , 11.5 g/dL in men, ,10.5 g/dL in women.
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12 vs. 18%, P, 0.001). Conversely, diuretic agents and calcium
channel blockers (CCB) were more commonly prescribed to
octogenarians (diuretics 93 vs. 89.5%, P, 0.05; CCB 18 vs. 14%,
P, 0.01), whereas prescriptions of nitrates and digoxin were
similar in both age groups. Anti-arrhythmic agents and
lipid-lowering drugs were used less frequently in the older group
(13 vs. 19%, P, 0.001 and 32 vs. 44%, P, 0.001, respectively).
In the subgroup of octogenarians with low-EF (EF  45%), the
use of ACE-I/ARBs (80 vs. 85%, P, 0.05), beta-blockers (60 vs.
69%, P, 0.01), combination ACE-I/ARBs þ beta-blockers (51 vs.
62.5%, P, 0.001), and aldosterone antagonists (48 vs. 58%, P,
0.01) remained lower than in younger subjects.
Comparison of heart failure therapy in EHFS II and EHFS I
Table 4 shows a comparison of HF prescriptions between EHFS II
and the previous EHFS I in the octogenarians. A significant increase
in prescription rates of HF-recommended drugs at discharge was
observed in EHFS II. This was shown for ACE-I/ARBs, beta-
blockers, and aldosterone antagonists. High doses of ACE-I/ARB/
beta-blockers and the combination of ACE-I/ARBs with
beta-blockers were also more frequently used in octogenarians
in EHFS II than in EHFS I. Similar findings were observed in the sub-
group of octogenarians with chronic HF and reduced EF (EF 
45%) (Figure 2).
Prescription rates over time
Figure 3 indicates HF prescription rates over time in the octogen-
arian group. During 12 months of FU from discharge, the
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Table 3 Biological findings and cardiac investigations by age group
Age  80 years (n ¼ 741) (21%) Age, 80 years (n ¼ 2836) (79%) P-value
Laboratory parameters
Haemoglobin (g/dL)a 12.5 (11.2–13.8) 13.2 (11.7–14.5) ,0.001a
Creatinine (mg/dL)a 1.3 (1.0–1.7) 1.2 (1.0–1.5) ,0.001a
GFR (MDRD equation) (mL/min)a 46.6 (35.5–61.3) 58.7 (43.5–74.7) ,0.001a
GFR, 60 mL/min 73% (523/720) 53% (1459/2768) ,0.001b
GFR, 30 mL/min 16% (118/720) 10% (276/2768) ,0.001b
Echocardiography
Echocardiography done 81% (598/739) 92% (2613 /2833) ,0.001b
Ejection Fraction (%)a 40 (30–52) 35 (25–48) ,0.001a
LVEF. 45% 39% (183/470) 28% (624/2260) ,0.001b
LVEDD (mm)a 53.4 (47.0–59.0) 59.0 (52.0–66.0) ,0.001a
Left atrial diameter (mm)a 46.0 (42.0–51.6) 47.0 (42.0–52.0) 0.177a
Moderate/severe aortic valve stenosis 16% (88/540) 7% (164/2435) ,0.001b
Coronary angiography
Coronary angiography reported 17% (124/720) 41% (1156/2788) ,0.001b
No significant coronary heart disease 19% (24/124) 32% (368/1156) 0.004b
Percutaneous coronary intervention 5% (35/739) 9% (264/2802) ,0.001b
Data are presented as percentage (number/population).
GFR, glomerular filtration rate; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter.
aMedian and quartiles, Mann–Whitney U test.
bPearson’s x2 test.
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Table 2 Baseline lifestyle measures by age group
Age  80 years
(n ¼ 741)
(21%)
Age, 80 years
(n ¼ 2836)
(79%)
P-value*
Domestic status
Living in own home 87% (617/709) 98% (2680/2734) ,0.001
Living alone 21% (144/673) 14% (362/2670) ,0.001
Living with spouse
or equal
31% (211/673) 64% (1717/2670) ,0.001
Living in special
accommodation
13% (92/709) 2% (54/2734) ,0.001
Need help for
services of caring
28% (124/437) 12% (259/2234) ,0.001
Help by relatives in
daily activities
41% (186/453) 32% (712/2207) ,0.001
Quality of life
Self-care problems 59% (270/456) 48% (1081/2261) ,0.001
Walking disorders 80% (364/455) 70% (1586/2261) ,0.001
Difficulties to
perform usual
activities
79% (357/453) 72% (1626/2257) 0.003
Pain or discomfort 64% (295/458) 66% (1484/2264) 0.641
Anxiety or
depression
55% (241/438) 57% (1249/2192) 0.450
Data are presented as percentage (number/population).
*P-values were calculated by Pearson’s x2 test.
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prescription of recommended HF therapies remained stable. Out
of the 448 octogenarians whose medication was recorded at 3
months, ACE-I/ARB had been discontinued since discharge in
4.0%, diuretics in 2.7%, beta-blockers in 2.5%, aldosterone antagon-
ists in 2.0%, and digitalis in 3.4%. On the other hand, these drugs
had been newly prescribed in 3.6, 2.0, 3.1, 2.7, and 2.9%, respect-
ively. From 3 to 12 months, medication was recorded for 288
octogenarians, the percentages of discontinuation were 5.9, 2.8,
5.2, 5.2, and 4.9%, and the percentages of new prescriptions 2.1,
2.8, 6.3, 5.2, and 3.5%, respectively.
Outcomes
In the overall population, 238 deaths were observed in-hospital,
263 at 3 months, and 319 between 3 and 12 months. During the
whole period of observation, overall mortality was higher in the
octogenarian group than in the younger group. This applied to
in-hospital mortality (10.7 vs. 5.6%, P, 0.001), to 3 month mor-
tality after discharge (13.5 vs. 6.8%, P, 0.001), as well as 12
month mortality after discharge (28.4 vs. 18.5%, P, 0.001)
(Figure 4). Similarly, MACE (death, stroke, and acute MI) were
more frequent in the older group in hospital (12.9 vs. 9.2%, P,
0.01), at 3 months (27.0 vs. 17.7%, P, 0.001), and at 12 months
after admission (41.7 vs. 29.6%, P, 0.001). Finally, rehospitaliza-
tion rates of survivors were higher in the younger group from dis-
charge to 3 months [0.140 per person-month vs. 0.106 per
person-month, rate ratio 1.32 (95% CI 1.11–1.56)] and from 3
to 12 month FU [0.074/month vs. 0.056/month, rate ratio 1.30
(95% CI 1.08–1.57)].
Predictors of death in octogenarians
We examined separately the factors predicting death in hospital
and during FU in the octogenarian group. The validation pro-
cedures suggested that, for predictive purposes, the effects in
the hospital mortality model may be overestimated by 15%
and the adjusted value of the C-statistic would be 0.767; effects
in the FU model may be overestimated by 30%. In-hospital mor-
tality was independently associated with age, signs of low cardiac
output/cardiogenic shock, STEMI, renal dysfunction, acute infec-
tion, and severe disability (confinement to bed) (Table 5). Age
remained a strong independent predictor of 1 year mortality in
octogenarians surviving at discharge, as well as disability (self-care
problems) and co-morbid factors including diabetes and renal dys-
function (Table 6). Prescription of ACE-I/ARBs and statins was
associated with a better outcome, whereas the use of beta-
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Table 4 Comparison of heart failure medications in discharged alive octogenarians with heart failure in Euro Heart
Survey I and II
EHFS II (n ¼ 662) EHFS I (n ¼ 2406) P-value*
Diuretics 93% (612/660) 92% (2209/2398) 0.604
ACE-I 65% (428/660) 53% (1262/2398) ,0.001
ARB 12% (81/661) 4% (93/2398) ,0.001
ACE-I or ARB 76% (503/661) 56% (1344/2398) ,0.001
High-dose ACE-I 26% (167/653) 16% (372/2311) ,0.001
High-dose ARB 5% (33/659) 0.5% (13/2395) ,0.001
High-dose ACE-I or ARB 30% (199/661) 16% (385/2398) ,0.001
Beta-blockers 53% (349/660) 25% (593/2398) ,0.001
High-dose beta-blockers 12% (79/659) 5% (123/2354) ,0.001
ACE-I or ARB and beta-blockers 42% (279/661) 15% (348/2398) ,0.001
Spironolactone/eplerenone 38% (251/660) 15% (355/2398) ,0.001
Digitalis 34% (222/660) 38% (919/2398) 0.027
Calcium channel blockers 18% (122/660) 21% (501/2398) 0.174
Data are presented as percentage (number/population).
ACE-I, angiotensin-converting enzyme-inhibitors; ARB, angiotensin receptor blockers.
*P-values were calculated by Pearson’s x2 test.
Figure 1 Heart failure medications in Euro Heart Failure
Survey II at discharge by age group. ACE-I, angiotensin-converting
enzyme-inhibitors; ARBs, angiotensin receptor blockers; BB,
beta-blockers; Aldo Ant, aldosterone antagonists.P-values were
calculated by Pearson’s x2 test.
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blockers at discharge was predictive of good outcome only in the
subgroup with reduced EF (EF  45%) [HR 0.56 (95% CI: 0.33–
0.94), P, 0.05]. EF as a continuous variable was not predictive
of in-hospital or follow up-mortality of the octogenarian popu-
lation in the multivariate model and was predictive of in-hospital
death only in the subgroup with reduced EF [OR 1.32 (95% CI
1.01–1.72) per 5% decrease].
Discussion
Clinical profile
We observed clinical differences between octogenarians and
younger patients consistent with previous studies.3,4,7,9 – 11 Older
subjects were more frequently women, had lower BMI, and
higher blood pressure levels. As observed previously in EHFS-I,3
the presence of co-morbidities (stroke, COPD, anaemia, renal
dysfunction, and neurological disorders) was also more
common in octogenarians,3,4,7,9 and the frequency of diabetes
was lower in older patients. This may be related to the high mor-
tality rate in patients with diabetes, reducing therefore the likeli-
hood of survival until the age of 80 years. Atrial fibrillation was
more often observed in the octogenarians4,9 – 11 and was
Figure 2 Comparison of heart failure medications at discharge
in octogenarians in Euro Heart Failure Survey I (n ¼ 542) and II
(n ¼ 158), EF, 45%. ACE-I, angiotensin-converting enzyme-
inhibitors; ARBs, angiotensin receptor blockers; BB, beta-
blockers; Aldo Ant, aldosterone antagonists. P-values were calcu-
lated by Pearson’s x2 test.
Figure 3 Heart failure prescription rates over time in the octo-
genarian group. ACE-I, angiotensin-converting enzyme-inhibitors;
ARBs, angiotensin receptor blockers; Aldo Ant, aldosterone
antagonists.
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Table 5 Predictors of hospital mortality in
octogenarians
Variable Bivariate odds ratio
(95% CI)a
Adjusted odds
ratio (95% CI)b
Age (per 5 year increase) 1.36 (1.01–1.82) 1.42 (1.04–1.95)
Cardiogenic shock 12.99 (5.28–31.97) 5.20 (1.77–15.33)
STEMI 3.02 (1.65–5.53) 3.62 (1.79–7.32)
SBP (per 10 mmHg
decrease)
1.19 (1.10–1.29) 1.09 (1.01–1.18)
Confinement to bed 4.31 (2.09–8.89) 3.08 (1.32–7.20)
Acute infection 1.79 (1.04–3.07) 1.96 (1.08–3.58)
Somnolence/confusion 3.48 (2.13–5.66) 1.97 (1.10–3.55)
Cold periphery 3.17 (1.79–5.60) 1.92 (1.00–3.69)
Creatinine (mg/dL) 1.69 (1.28–2.24) 1.63 (1.17–2.27)
C ¼ 0.793, Hosmer–Lemeshow test P ¼ 0.60.
STEMI, ST-segment elevation myocardial infarction; SBP, systolic blood pressure.
aCalculated by simple logistic regression separately for each variable.
bCalculated by multiple logistic regression, including all the factors shown in the
table as co-variates.
Figure 4 Overall mortality after discharge according to age.
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present in half of the patients as in EHFS I.3 Interestingly, new
onset HF (de novo) was more frequently reported in the octogen-
arian group. To our knowledge, this has not been investigated in
other studies. The reasons for the increased rate of de novo HF
episode in the octogenarians might be related to the high fre-
quency of preserved EF after 80 years.
Lifestyle
Our findings indicate a high rate of dependency and a low quality of
life in elderly HF people. These results suggest a stronger decline in
functional status in octogenarians with HF compared with those
without HF.21,22 This increased disability was associated to a
higher need for household assistance services in older persons.
Overall, our results suggest that the elderly HF patients are very
frail patients. Thus, there is room for improving daily care by multi-
disciplinary approaches in these patients.
Investigations
We observed a marked improvement in the rate of performance
of echocardiography in octogenarians people compared with pre-
vious studies. In octogenarian patients, cardiac function was
assessed twice more often in EHF II than in EHFS I.3 These
results can be explained by an improvement in health care
quality over the past years or by the fact that more patients
enrolled in EHFS II were referred to cardiology departments
than in EHFS I.
Nevertheless, assessment of cardiac function remained less
common in older patients. Left ventricular EF was more frequently
preserved in the older subjects as reported in other studies.23,24
Finally, coronary angiography was twice less often performed in
octogenarians than in younger subjects.25 This observation may
be partly explained by the high rate of renal dysfunction and of
co-morbidities in the older group.
Treatment
As observed previously, there was an underprescription of rec-
ommended HF medications, in the octogenarian patients enrolled
in EHFS II.3,4,7,9,26 The difference was mainly observed for beta-
blockers and aldosterone antagonists, which are less often used
in octogenarians. A number of factors related to patients
(general condition, co-morbidities, poor tolerance) or to prescri-
bers (lack of awareness of evidence-based guidelines, fear of side
effects, focus on symptomatic improvement rather than on
outcome) have been suggested to explain this situation.27
However, a striking finding of our survey was the substantial
increase in the rate of prescription of recommended medications
at discharge when compared with the first European Survey.3
This was observed in the overall HF population as well as in the
subgroup with reduced EF. In this subset, the rate of prescription
of ACE-I/ARBs was .80%, beta-blocker use was nearly doubled
when compared with EHFS I, and half of the population received
the combination. Finally, we observed a much higher rate of pre-
scription of aldosterone antagonists than previously reported in
EHFS I. Caution has been recommended in the use of this class
in the very elderly because of the risk of potentially severe side
effects in relation to the high prevalence of renal dysfunction.28
It is likely that the inclusion criteria of the current survey,
namely the context of acute/decompensated HF, played a role to
explain this finding.
There was also an increase in the rate of prescription of rec-
ommended medications from admission to discharge, and, most
importantly, the improvement in the rate of prescription was sus-
tained over the 12 month FU period in survivors. Particularly, very
little changes in drug therapy occur after hospital discharge. These
results have been obtained also in other studies29 and emphasize
the major role of the early treatment initiation for the long-term
HF therapy in the elderly. Overall, our results suggest an improve-
ment in treatment modalities in the very elderly with HF. This
might reflect the impact of the large dissemination of international
guidelines and a better knowledge of the objectives of the treat-
ment, particularly among cardiologists.30
Outcomes
Few studies have so far followed up cohorts of elderly patients
over 80 years for 1 year after index hospitalization. In-hospital, 3
month and 12 month mortality rates were extremely high in the
octogenarian population. The rate of major cardiovascular events
observed during the FU period was also significantly increased.
Our results also confirm that age appears as a strong and indepen-
dent predictor of mortality in HF patients.31,32
Factors associated with mortality in hospital and during FU were
different. In-hospital death was mainly related to acute clinical con-
ditions, whereas long-term mortality was associated with disabil-
ity33 and the presence of co-morbidities such as diabetes and
renal dysfunction. As reported previously, we showed that renal
function is a strong predictor of both in-hospital and FU mor-
tality,34 whereas anaemia was not associated with poor outcome
in octogenarians (as observed in EHFS I3). Low EF, a strong predic-
tor of mortality in younger population,35 was not identified here as
an independent factor in the octogenarian population, unlike the
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Table 6 Predictors of follow-up mortality after
discharge in octogenarians
Variable Crude hazard ratio
(95% CI)a
Adjusted hazard ratio
(95% CI)b
Age (per 5 year
increase)
1.55 (1.29–1.87) 1.51 (1.24–1.84)
SBP (per 10 mmHg
decrease)
1.05 (1.00–1.10) 1.04 (0.99–1.09)
Diabetes mellitus 1.36 (0.98–1.89) 1.56 (1.12–2.18)
Self-care problems 1.82 (1.21–2.75) 1.60 (1.03–2.49)
Creatinine (mg/dL) 1.51 (1.26–1.80) 1.48 (1.21–1.80)
ACE-inhibitors/ARB 0.48 (0.35–0.66) 0.56 (0.40–0.79)
Statins 0.59 (0.41–0.85) 0.67 (0.45–0.99)
Beta-blockers 0.72 (0.53–0.98) 0.87 (0.63–1.20)
SBP, systolic blood pressure; ARB, angiotensin receptor blockers.
aCalculated by simple Cox regression separately for each variable.
bCalculated by multiple Cox regression, including all the factors shown in the table
as co-variates.
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report from a recent national survey.4 This finding may be due to
the high prevalence of HF with preserved EF, and, indeed, only
one-fifth of the available echo results showed an EF, 30%. The
use of ACE-I or ARBs was associated with a better 1 year
outcome.36 –39 This finding is consistent with the previous EHFS
I and suggests that ACE-I/ARBs should be used over 80 years in
HF patients. The fact that prescription of beta-blockers was not
associated to improvement in 1 year mortality in the overall popu-
lation could be related to the high proportion of HF with pre-
served EF or to the fact that the limited size of the population
taking this medication did not allow to show benefit.
Surprisingly, we observed a higher rehospitalization rate in
younger people. This might be due to the fact that octogenarians
had a higher mortality during hospitalization. So the more severe
patients were likely to die early, resulting in a competing risk.
Limitations
Our survey was an observational study conducted only in patients
hospitalized with HF. Sites that volunteered for the study included
a majority of cardiology departments. Therefore, the proportion of
octogenarians referred to internal medicine wards was lower in
the second survey when compared with the first one. This fact
may partly explain the improvement in HF management observed
here. It has been demonstrated in other studies that patients
treated by cardiologists are more likely to receive
HF-recommended drugs on admission and at discharge compared
with patients treated by other physicians.30 Our results are in line
with these findings and suggest that cardiologists are more aware
of and better apply the guidelines for HF therapy in the elderly.
Moreover, the observed differences in HF prescriptions between
the two surveys were not related to different frequencies of
co-morbidities. Indeed, at discharge, the prevalence of renal dys-
function, COPD, stroke, and anaemia was similar in EHFS I and
EHFS II.
In our study, high disability was observed in HF octogenarians on
the basis of self-related questionnaire but we did not record all
co-morbid factors associated with ageing, and this might have
resulted in an underestimate of the overall prevalence. Particularly,
presence of dementia or cancer was not evaluated and could not
be included in the predictive model of mortality. Moreover, no
central laboratory was used for echocardiography assessment.
Therefore, caution is needed in the interpretation of cardiac
function.
The effect of treatments on outcome must be cautiously inter-
preted in the context of an observational study which was not
designed to evaluate the impact of prescriptions on prognosis. Fur-
thermore, the inclusion criteria used in EHFS II were partly differ-
ent from those used in EHFS I, and patients were not exactly
superimposable, but the clinical profile of the octogenarians was
similar in the two surveys, particularly in terms of co-morbidities.
Moreover, the diagnostic criteria used in the current survey
were more robust than those of EHFS I, where patients with sus-
pected or confirmed HF were included. Finally, the comparison of
treatment modalities in the octogenarians in the two surveys
showed an improvement not only in the overall population but
also and more specially in the low-EF subgroup of patients, a
domain where international guidelines are well established.
Conclusions
We report here a large cohort of octogenarian people with acute/
decompensated HF. Compared with younger patients, octogenar-
ians had more co-morbidities and a higher mortality rate over 12
months of FU. Diagnostic procedures and medical management
remain suboptimal but are improving when compared with the
previous European survey.
Conflict of interest: none declared.
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